• AstraZeneca and FibroGen receive approval to market roxadustat in China pharmaceutical-technology
    December 21, 2018
    AstraZeneca and its partner FibroGen Medical Technology Development have obtained approval from China’s National Medical Products Administration (NMPA) to market roxadustat for the treatment of anaemia caused due to chronic kidney disease (CKD).....
PharmaSources Customer Service